Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Clinical Trial

Official title:
Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia

Status Terminated

Clinical Trial Summary

This is a single center, single arm, open-label pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART22" cells) administered in split fractions, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Clinical Trial Details

NCT number	NCT02588456
Study type	Interventional
Source	University of Pennsylvania
Contact
Status	Terminated
Phase	Phase 1
Start date	October 2015
Completion date	September 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05105867` - CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies	Early Phase 1
Recruiting	`NCT04690595` - BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL	Phase 1
Recruiting	`NCT05054257` - CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma	Phase 1
Withdrawn	`NCT02215629` - Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia	Phase 1